Loss of NAT2, a non-essential enzyme involved in drug metabolism, in colorectal cancers emerged as an attractive target conceptually different from synthetic lethality (ENO2, PRMT5, ME3) or targeting genes essential for cell survival (POLR2A, RPA70, or PSMC2). The gene discussed is POLR2A; the disease is colorectal cancer.